Guardant Health operates through three main business segments: Oncology, Screening, and Biopharma & Data. Its core Oncology business provides clinical testing services, including the Guardant360 and Guardant Reveal tests, which are used for therapy selection and recurrence monitoring in advanced and early-stage cancers. The Screening segment is driven by the Shield blood test, designed for the early detection of colorectal cancer. Additionally, the Biopharma & Data segment partners with pharmaceutical companies to support companion diagnostic development and clinical trials. By processing patient samples in its own CLIA-certified laboratories, Guardant Health competes directly with traditional tissue biopsy methods and other diagnostic testing providers.
